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Abstract
Lethal mutagenesis is an antiviral strategy consisting of virus extinction associated with enhanced mutagenesis. The use of
non-mutagenic antiviral inhibitors has faced the problem of selection of inhibitor-resistant virus mutants. Quasispecies
dynamics predicts, and clinical results have confirmed, that combination therapy has an advantage over monotherapy to
delay or prevent selection of inhibitor-escape mutants. Using ribavirin-mediated mutagenesis of foot-and-mouth disease
virus (FMDV), here we show that, contrary to expectations, sequential administration of the antiviral inhibitor guanidine (GU)
first, followed by ribavirin, is more effective than combination therapy with the two drugs, or than either drug used
individually. Coelectroporation experiments suggest that limited inhibition of replication of interfering mutants by GU may
contribute to the benefits of the sequential treatment. In lethal mutagenesis, a sequential inhibitor-mutagen treatment can
be more effective than the corresponding combination treatment to drive a virus towards extinction. Such an advantage is
also supported by a theoretical model for the evolution of a viral population under the action of increased mutagenesis in
the presence of an inhibitor of viral replication. The model suggests that benefits of the sequential treatment are due to the
involvement of a mutagenic agent, and to competition for susceptible cells exerted by the mutant spectrum. The results
may impact lethal mutagenesis-based protocols, as well as current antiviral therapies involving ribavirin.
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Introduction
The capacity of rapidly multiplying parasites to adapt to the
changing environment of their host organisms is a formidable
obstacle for the control of the diseases they bring about, and an
unsolved problem in medical and veterinary practice. RNA viruses
are remarkably adaptable due to their elevated mutation rates and
quasispecies dynamics [1–4]. A means to compromise the
replication of highly variable RNA viruses is to enhance their
mutation rates above the maximum level compatible with
expression of their genetic program and completion of their life
cycle. The existence of an error threshold for genetic stability was
predicted by quasispecies theory, that established a correlation
between the average error rate and the complexity of the genetic
information that can be reproducibly maintained [1–3,5]. This
concept has been supported by additional theoretical treatments
[5–18]. RNA virus genomes and other RNA genetic elements have
limited length (encoded information), and, accordingly, they
tolerate the high mutation rates that they display during replication
[19–21]. If in the course of virus replication the error rateis elevated
above the error threshold, the result should be the extinction of the
virus, in a process that has been termed lethal mutagenesis.
Extensive experimental evidence has documented viral extinction
upon replication of RNA viruses in the presence of mutagenic
agents, in particular mutagenic nucleoside analogues [22–35].
In an exploration of variables that could influence extinction of
the picornavirus foot-and-mouth disease virus (FMDV), it was
noted that low viral fitness and low viral load favored extinction
[33,36]. As a consequence, combinations of mutagenic agents and
antiviral inhibitors were more effective than mutagenic agents
alone in driving viral populations towards extinction [36–39]. The
advantage of a combination of a mutagenic agent and an antiviral
inhibitor in lethal mutagenesis was in agreement with the
requirement of combination treatments to delay or prevent
selection of escape mutants when employing non-mutagenic
antiviral inhibitors, as supported by theoretical studies and clinical
observations [40–46].
The nucleoside analogue ribavirin [1-(b-D-ribofuranosyl)-1H-
1,2,4-triazole-3-carboxamide] (R)isa licensedantiviral agentshown
to be mutagenic for a number of RNA viruses [47–53], currently
used in investigations on lethal mutagenesis. Viral mutants with
decreased sensitivity to R have been described for several viruses,
including the picornaviruses poliovirus (PV) and FMDV [54–59].
The presence of a mutation that decreased the sensitivity of FMDV
to R resulted in extinction failure when the virus was replicated in
the presence of high concentrations of R [60]. Extinction was
achieved with an alternative mutagenic treatment with 5-fluoro-
uracil [60]. Therefore, it is important to understand the molecular
events that underlie virus extinction by mutagenic agents and to
explore protocols that avoid selection of escape mutants.
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choriomeningitis virus (LCMV) subjected to lethal mutagenesis
underwent a decrease of specific infectivity (with loss of infectivity
preceding loss of RNA replication capacity), and pre-extinction,
mutagenized RNA interfered with replication of infectious RNA
[27,61]. These results were further supported by simulations in
silico, and suggested that interference by defective (non-infectious
but replication-competent) genomes could contribute to loss of
infectivity. These defective genomes were termed defectors, and
their involvement in loss of infectivity led to the proposal of the
lethal defection model of virus extinction, [27,61], a model which
was further strengthened by additional theoretical studies [62]. In
agreement with this proposal, specific capsid and polymerase
mutants of FMDV exerted complementation (at early times post-
electroporation) and interference (at late times post-electropora-
tion) when co-electroporated into cells together with infectious
FMDV RNA [63]. Related FMDV mutants that were not
competent in RNA replication did not exert any detectable
interference [63]. In line with these observations, replication of
drug-resistant poliovirus was inhibited by trans-acting, dominant
negative mutants [64]. Therefore, three critical interconnected
parameters have been identified as playing a role in viral
extinction by lethal mutagenesis: mutation rate, interference by
defector genomes, and viral load; the latter can be decreased by
the presence of antiviral inhibitors [33,61,63,65].
The combined use of mutagenic agents and antiviral inhibitors
poses an evolutionary and a virological riddle to the system. First,
the mutagenic agent, that is included in the drug cocktail, can
favor the generation of viral mutants resistant to the inhibitors co-
administered with the mutagen [36,38]. Second, if intracellular
replication is necessary for mutants to exert interference [63], the
presence of an antiviral inhibitor together with the mutagenic
agent may jeopardize the interfering activity of mutants by
preventing or diminishing their accumulation during mutagenesis.
However, if inhibitor-resistant mutants are generated, they could
contribute defector genomes induced by the mutagen. Here we
address this key issue using FMDV, specific interfering capsid and
polymerase FMDV mutants, the inhibitor of FMDV replication
guanidinium hydrochloride (GU), and R.
R eliminates FMDV from persistently and cytolytically infected
cells in culture, and its mechanism of action includes mutagenesis
of the viral RNA [59,66,67]. Failure to extinguish FMDV by a
sequential treatment with either fluorouracil or R first, followed by
GU, was systematically associated with selection of GU-resistant
FMDV mutants, with amino acid replacements in non-structural
protein 2C [36,37,60] (Perales et al., unpublished results). Here we
show that, contrary to expectations from antiviral designs with
non-mutagenic inhibitors, a sequential treatment first with GU
and then with R can be more effective in driving the virus to
extinction than the administration of GU and R in combination.
Quantification of the interference exerted by specific FMDV
mutants on the replication of standard FMDV suggests that the
molecular basis of the advantage of the sequential treatment is that
interfering FMDV mutants can exert a suppressive activity in the
presence of R, when GU is not present. However, the presence of
GU at the same time than R in the combination treatment would
jeopardize the interfering activity of the mutants by inhibiting their
replication, thereby contributing to virus survival. The results are
supported by a theoretical model that predicts the evolution of a
viral population in the presence of a mutagenic agent and an
antiviral inhibitor. From a practical point of view, the proposed
treatment protocol has the advantage that the simultaneous
administration of two drugs is avoided, and that low mutagen
doses may be sufficient to effect viral clearance.
Results
Effect of guanidine concentration on foot-and-mouth
disease virus replication and selection of escape mutants
To compare a sequential versus combination treatment
involving GU and R, we first determined the maximum GU
concentration that permitted at least two passages of FMDV
pMT28 (virus rescued from an infectious transcript; see
Materials and Methods) with a decrease of viral load, prior to
dominance of GU-resistant mutants [36,37]. The results
(Figure 1) indicate that there is a recovery of virus infectivity
in the presence of GU concentrations ranging from 8 to 18 mM,
but not 20 mM, and this is compatible with the dominance of
GU-resistant mutants, as we have previously shown [36,37]. GU
concentrations of 16, 18 and 20 mM led to a decrease in virus
progeny production for at least two consecutive passages, and,
therefore, these GU concentrations were chosen to compare the
efficacy of a sequential versus combination treatment involving
GU and R.
Benefits of inhibitor-mutagen sequential treatment
versus inhibitor+mutagen combination treatment
A sequential treatment first with GU and then with R was
compared with treatment with R or GU alone, and with a
combination treatment in which the inhibitor and the mutagenic
agent were administered simultaneously. Drug doses and times of
exposure were comparable in the different treatment protocols.
To this aim, FMDV pMT28 populations were subjected either to
one passage in the presence of GU (16, 18 or 20 mM) followed by
Author Summary
RNA viruses are associated with many important human
and animal diseases such as AIDS, influenza, hemorrhagic
fevers and several forms of hepatitis. RNA viruses mutate
at very high rates and, therefore, can adapt easily to
environmental changes. Viral mutants resistant to antivi-
ral inhibitors are readily selected, resulting in treatment
failure. The simultaneous administration of three or more
inhibitors is a means to prevent or delay selection of
resistant mutants. A new antiviral strategy termed lethal
mutagenesis is presently under investigation. It consists
of the administration of mutagenic agents to elevate the
mutation rate of the virus above the maximum level
compatible with virus infectivity, without mutagenizing
the host cells. Since low amounts of virus are extin-
guished more easily, the combination of a mutagen and
inhibitor was more efficient than a mutagen alone in
driving virus to extinction. Here we show that foot-and-
mouth disease virus replicating in cell culture can be
extinguished more easily when the inhibitor guanidine is
administered first, followed by the mutagenic agent
ribavirin, than when both drugs are administered
simultaneously. Interfering mutants that contribute to
extinction were active in the presence of ribavirin but not
in the presence of guanidine. This observation provides a
mechanism for the advantage of the sequential versus
the combination treatment. This unexpected effective-
ness of a sequential treatment is supported by a
theoretical model of virus evolution in the presence of
the inhibitor and the mutagen. The results can have an
application for future lethal mutagenesis protocols and
for current antiviral treatments that involve the antiviral
agent ribavirin when it acts as a mutagen.
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the presence of a combination of GU (16, 18 or 20 mM) and R
(5 mM), or at least five passages in the presence of either R
(5 mM) or GU (16, 18 or 20 mM) alone (Figure 2A). The
sequential treatment is abbreviated as +GU,+R, and the
combination treatment as [+GU+R]. The results (Figure 2B, C,
D) show that the decrease in virus titer and in viral RNA levels
was more rapid when GU was applied first and then R
sequentially, as compared with the other treatment protocols.
The second most effective treatment was achieved with the
administration of GU and R at the same time, in a combination
treatment [+GU+R]. At each passage, the virus titer and virus
RNA levels attained one or more logarithms lower level with the
sequential +GU,+R treatment than with the combination
treatment (Figure 2B, C, D) (p,0.008 for virus titer in all cases;
p,0.0001 for viral RNA levels in all cases; Student’s t test). The
decrease in virus titer and viral RNA levels was more accentuated
as the GU concentration was increased. To ascertain that the
decrease in the viral replication correlates with the extinction of
the viral population, RT-PCR amplifications for every passage
were performed. FMDV is considered extinct when no infectivity
and no viral RNA can be detected in the cell culture supernatant,
using a highy sensitive RT-PCR protocol, and after 3 blind
passages in the absence of any drug (see Materials and Methods
for further details). The advantage of the sequential treatment
was evidenced by loss of FMDV-specific genetic material,
indicative of virus extinction, at the same or at earlier passages
for sequential than either combination treatment or treatment
with GU or R alone (Figure 2E). The results using GU or R alone
showed a recovery in virus titer and RNA levels for GU
concentrations of 16 mM and 18 mM, whereas virus was not
extinguished until passage 6 using R alone.
Interference by specific FMDV mutants is exerted in the
presence of ribavirin, but suppressed by GU
The advantage of the sequential +GU,+R over the combination
[+GU+R] treatment was surprising in view of the previously
established (and broadly accepted) requirement of a combination
therapy to minimize or prevent selection of viral mutants resistant
to antiviral agents [40–46]. We suspected that the critical
difference could be the involvement of a mutagenic agent in the
treatment. Mutants generated in the course of R mutagenesis may
play an important role in the extinction of RNA viruses during
lethal mutagenesis treatments [27,62,63]. Thus, one interpretation
of the lower infectivity and viral loads as a result of the sequential
+GU,+R treatment over the combination [+GU+R] treatment is
that the interfering mutants generated by R-mutagenesis might
have been suppressed by GU when this inhibitor is added at the
same time. To investigate this possibility, we used previously
characterized interfering and non-interfering capsid and polymer-
ase mutants of FMDV [63]. BHK-21 cells were co-electroporated
with standard, infectious FMDV RNA and combinations of either
interfering FMDV mutants or of non-interfering FMDV mutants,
in the absence or presence of GU and R. The concentrations of
GU and R that decreased at least one logarithm the infectious
progeny production at 3 hours post-electroporation were previ-
ously determined (data not shown). The results (Figure 3 and
Table 1) show that the interfering combination of capsid mutant
Q2027A and polymerase mutant MD exerted an interference in
the presence of R at all times post-electroporation tested. In
contrast, in the presence of GU, the interference decreased
significatively at late times post-electroporation (Figure 3A). The
average interference (of the values at 3, 5 and 6 h post-
electroporation) exerted by the mutant combination Q2027A+
MD was 81% in the absence of GU and 61% in the presence of
Figure 1. Effect of guanidine (GU) concentration on the yield of progeny FMDV pMT28. Passages were carried out by infecting 2610
6
BHK-21cells with virus pMT28, in the presence of increasing concentrations of GU, as indicated in the boxes on the right. The initial multiplicity of
infection (MOI) was 1–2 PFU/cell. For subsequent passages, 0.2 ml of supernatant from the previous passage were used, resulting in MOIs of 10
25 to
10
21 PFU/cell in the presence of GU. Conditions for the infections, treatment with guanidine hydrochloride, and for determination of FMDV
infectivity by plaque assay are detailed in Materials and Methods. The discontinuous line indicates the limit of measurement of infectivity values.
doi:10.1371/journal.ppat.1000658.g001
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PLoS Pathogens | www.plospathogens.org 3 November 2009 | Volume 5 | Issue 11 | e1000658Figure 2. Sequential versus combination treatment with guanidine (GU), and ribavirin (R) on progeny production of FMDV pMT28.
(A) Scheme of the passage protocol used for the different treatments compared in the present study. Passages that involve ribavirin (R) treatment are
highlighted in red. Note that for comparison, one passage in the presence of the combination [+GU+R] was considered equivalent to the sequential
+GU, +R passages; this is indicated with ‘p2’, ‘p3’, ‘p4’ in the series involving the combination treatment. (B, C, D) BHK-21 cells were infected with
pMT28 in the presence of either GU [16, 18 or 20 mM], or R (5 mM), or the combination of GU and R. The only difference in the experiments described
in (B), (C) and (D) is the concentration of GU, which was 16 mM for the assays in panels B, 18 mM in panel C and 20 mM in panel D. The combination
treatment is indicated in brackets, while in the sequential treatment the order of administration of GU and R is separated by a comma. Passages were
carried out by infecting 2610
6 BHK-21 cells with virus (0.2 ml of supernatant from the previous passage resulting in MOIs of 10
26 to 10
21 PFU cell),
and infectivities and FMDV RNA levels were determined as detailed in Materials and Methods. The discontinuous lines in the virus titer and RNA
quantification indicate the limit of measurement of infectivity values, and the limit of detection of FMDV RNA for real time PCR quantification,
respectively. Each value represents the mean 6 standard deviation (error bars) from triplicate determinations. (E) RT-PCR amplifications used to
detect viral RNA in the cell culture supernatants, to monitor virus extinction. The sample analyzed and passage number (nomenclature of part A and
B) are indicated above each panel. The presence or absence of a visible band after RT-PCR amplification, and the occurrence or not of extinction are
indicated as + or 2; the first passage in which extinction was observed is boxed in red. Molecular size markers (Hind III-digested Ø29 DNA; the
corresponding sizes [base pairs] are indicated on the left); C-, negative control; amplification without RNA; C+, PCR positive control, are shown for the
first panel only, but they were included in all the amplification assays. Conditions of the infections, mutagenic treatment, determination of infectivity,
quantification of FMDV RNA, and RT-PCR amplification are detailed in Materials and Methods.
doi:10.1371/journal.ppat.1000658.g002
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decrease with a 95% confidence interval of 29.6% to 10.4%;
Student’s t test). In contrast, the average interference exerted by
the same mutant combination was 81% in the absence of R and
94% in the presence of R. This increase is statistically significant
(p=0.005 for the 12% increase with a 95% confidence interval of
6.37% to 19.58%). When expressed as the interference measured
at each time point (Table 1) the results indicate strong suppresion
of interference by GU (but not by R) at the late time point at
which the Q2027A+MD combination exerts its highest effect [63].
The results suggest that GU may inhibit replication of defector
genomes, while R may contribute to the generation of additional
defector genomes (see Discussion). No significant differences were
observed in the virus titers produced in the presence of the
combination of non-interfering mutants DMD+D3 in the presence
and absence of GU (p=0,5; Student’s t test), as expected. The 2C-
coding region of the progeny of the RNAs that were electropo-
rated in the presence of GU was sequenced. No mutations
associated with GU-resistance were detected in any sample. Thus,
the decrease in interference in the presence of GU, upon
replication immediately following electroporation, was not due
to replication of GU-resistant mutants. These experimental results
suggest that the mechanism by which the sequential treatment is
more efficient than the combination treatment in decreasing the
viral load and driving a virus towards extinction, is that in the
sequential treatment the inhibitor cannot prevent replication of
defector genomes that are generated by the mutagenic agent.
The advantage of sequential treatment is supported by a
theoretical model
The lethal defection model of virus extinction was proposed on
the basis of experimental results with FMDV and LCMV and of a
computational model with virtual viable and defective genomes
that replicated in the course of a persistent LCMV infection of
BHK-21 cells [27]. Current evidence suggests that trans-active
viral gene products harboring amino acid substitutions may impair
functions of standard genomes whenever protein complexes are
required for function (homo and hetero-polymers among viral
proteins or between viral and host proteins). For further discussion
Figure 3. Effects of ribavirin (R) and guanidinium (GU) on the interference on FMDV replication exerted by capsid and 3D
polymerase mutants. (A) Cells were mock-electroporated (control), or electroporated with 2 mg of pMT28 transcript (expresing FMDV C-S8c1), or
co-electroporated with a mixture of transcripts obtained from pMT28 and from capsid mutant Q2027A and 3D polymerase mutant MD [63]. +R and
+GU indicate the presence of R (1 mM) or GU (2 mM), respectively, as indicated in the box on the right. The ratio of pMT28 RNA to the total amount
of mutant RNA was 1:10, and the total amount of FMDV RNA was the same in each electroporation assay. Infectivity values were determined in
triplicate at the indicated hours post-electroporation. Virus titers are expressed as percentage of the titers produced, relative to those producedb y
pMT28 RNA at the corresponding hours post-electroporation, taken as 100%. (B) Same as in (A) but using in the coelectroporations RNA from non-
interfering polymerase mutants DMD and D3 [63]. In (A) and (B), no infectivity was obtained from the mock-electroporated samples (control box in
dark grey, not visible). The origin of FMDV mutants, and procedures for titration of virus are detailed in Materials and Methods.
doi:10.1371/journal.ppat.1000658.g003
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realistic parameters for viral genome replication and mutation
rates, the model predicted a decisive participation of defector
genomes in the extinction of the viable class of genomes [27,60].
Therefore, we have now developed another model for the
evolution of viral populations that replicate in serial cytolytic
infections under increased mutagenesis, and in the presence of an
inhibitor of viral replication. We have asked whether this new
model predicts the experimental results reported here, in
particular an advantage of sequential over combination treatment.
The model considers four different types of individuals in the
population: wild-type susceptible to the inhibitor (WTs), defective
susceptible to the inhibitor (Ds), wild-type resistant to the inhibitor
(WTr), and defective resistant to the inhibitor (Dr), but does not
consider any direct interference exerted by the defective genomes
on wild type replication (Figure 4). Individuals of the wild-type are
able to replicate by themselves when they infect a cell; defective
individuals cannot replicate in absence of wild-type individuals.
WTs and Ds replicate more slowly in the presence than in the
absence of the inhibitor, while WTr and Dr are not affected by the
inhibitor. The natural mutation rate during genome replication is
w, which for simplicity is equated to the rate of production of
defective forms, generated upon replication of the wild type.
Individuals resistant to the inhibitor are generated at a rate m=k
w, with k=10
23 (values for the coefficient k ranging from 10
22 to
10
25 do not affect the results qualitatively). Hence, an increase in
the mutation rate has two effects: a larger number of defective
genomes are generated, and the probability to develop resistance
to the inhibitor increases (Figure 4).
We consider a total of N=10
7 cells which can be infected at
each passage. The maximum number of virions entering a cell is
one. The initial virus replicates inside the cell for a number of
cycles G=5. When the inhibitor is absent, the number of progeny
genomes per parental genome is given the value R=1.5 for wild-
type individuals, and r=1 for defective individuals. When the
inhibitor is present, the replicative parameters R and r are
multiplied by a factor 0,i,1. The natural mutation rate is set to
w=0.05 in the examples that follow. At passage 0, the population
is composed only of individuals sensitive to the inhibitor; resistant
individuals will be generated by mutation. Replication inside each
cell follows a deterministic process according to the above
description. Let us call WTs(g), Ds(g), WTr(g), and Dr(g) the four
populations at replication cycle g. In one replication cycle, the
number of particles produced is
WTs(g+1)=Ri(12m2w) WTs(g)
WTr(g+1)=R (12w) WTr(g)+Rim WTs(g)
Ds(g+1)=i Ds(g)+RiwWTs(g)
Dr(g+1)=Dr(g)+RwWTr(g)
We define the factor of inhibition (to be given in percent) as
fi=100 * (12i), such that fi=0% indicates no inhibition (in the
equations above, parameter i=1) and complete inhibition (or
forbidding replication), corresponds to fi=100% (i=0). The total
population produced by the cell in G viral replication cycles is the
result of iterating G times the equations that define the model. The
total viral population P after one passage is the sum of the
production by the N cells. This final viral population is then used
to seed a new ensemble of N cells, to start the next passage. The
average number of virions entering each cell is P/N, unless it
exceeds one (which is the maximum we allow in these examples).
A natural population evolves through passages with a mutation
rate w=0.05, and in the absence of inhibitor (i=1). The addition of
a mutagen changes the mutation rate to a higher value of w, while
the addition of an inhibitor diminishes the replication rate of
susceptible particles in an amount i,1. The example given in
Figure 5A demonstrates the dynamics of the model in some of the
experimental situations reported in the manuscript. When no
mutagen and no inhibitor are present, the population evolving
under the natural parameters reaches a high titer (measured as the
number of wild-type individuals). When a mutagen is added (in
practice, the value of w is set to 0.6), extinction after several passages
occurs. Differentcurvesshow how thepopulationrecoverswhen the
treatment with the mutagen is interrupted beginning at passages
two, three, and four. This behavior is that observed when GU-
escape mutants are selected in populations treated with a mutagen
and GU ([36,37,60]; Perales et al., unpublished results).
In the second case (Figure 5B), we describe the dynamics when
different amounts of inhibitor are used, analogous to the
experimental assays presented in Figure 1. Increasing concentra-
tions of inhibitor result in a gradually steeper decrease in the
number of progeny particles. However, except for the highest
inhibitor concentration tested, resistant mutants are selected, and
progeny production finally reaches the level attained in the
absence of inhibitor. The simulation agrees with the experimental
results (compare Figure 1 and Figure 5B).
Table 1. Interference by specific FMDV mutant combinations.
Components present during FMDV (pMT28) genome replication
a Interference (%)
b
pMT28 Q2027+MD DMD+D3 +GU +R 3 h5 h6 h




++ 222 72.0 75.0 86.0
++ 2 + 2 88.5 82.2 32.8
++ 22+ 96.7 92.5 94.9
+ 2 + 22 ND
c ND
c 34.2
+ 2 ++2 21.7 14.2 21.6
+ 2 + 2 + 77.8 32.5 13.6
aInterference was determined by measuring infectious progeny production after co-electroporation of pMT28 RNA alone (first row) or with mixtures of mutant FMDV
RNAs (either Q2027A+MD or DMD+D3) in the absence (2) or presence (+) of guanidinium (GU) or ribavirin (R), as indicated. The origin of FMDV mutant RNAs and
experimental procedures are detailed in Materials and Methods.
bInterference (%) is defined as [titer pMT28–titer pMT28 (plus indicated components)/titer pMT28]6100. Values are the average of three determinations, at 3 h, 5 h and
6 h post-electroporation. Virus titers (expressed as percentage of the titer obtained for pMT28 alone) and standard deviations are given in Figure 3.
cNA, not applicable; ND, not detectable.
doi:10.1371/journal.ppat.1000658.t001
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under different combinations of inhibitor and mutagen. The
examples are chosen to mimic the experiments presented in
Figure 2. Sequential therapy causes extinction faster than
combination therapy, and a contributing factor is the appearance
and fixation of resistant mutants during the combination treatment,
promoted by the mutagen. The superiority of sequential therapy is
observed over a broad range of parameters, though it is not generic
for this model. The role played by parameters such as the
replication rate of the wild type, the number of replication cycles
inside a cell, or the relative effect of mutagen and inhibitor and how
they interact when applied jointly will be explored in future studies
(see also Discussion). Both, the experimental results and the
theoretical model (for the parameters used) suggest an approxi-
mately ten-fold increase in the viral yield in the case of combination
therapy compared to sequential therapy.
Discussion
One of the major consequences of quasispecies dynamics for
pathogenic RNA viruses is that subpopulations of viruses from the
mutant spectra, that harbor mutations that decrease the sensitivity
to antiviral inhibitors, are rapidly selected (review in [68]). Lethal
mutagenesis exploits high mutation rates of RNA viruses [19,20]
to increase the average error rate during viral replication even
further, until meaningful genetic information and viral functions
deteriorate, and the virus is extinguished [22–35].
New nucleoside analogues are currently investigated as possible
virus-specific mutagenic agents that could be included in lethal
mutagenesis protocols [22,29,35,69–71]. In addition to safety
issues concerning adverse activity on the host cells (related to
mutagenesis of cellular DNA, or other effects), the administration
of virus-specific mutagenic base or nucleoside analogues requires
careful consideration of protocols when antiviral inhibitors are co-
administered with the mutagenic agents [72]. This has become
particularly relevant with recent observations that suggest that
replication-competent subsets of defective viral genome subpop-
ulations termed defectors may participate in the process of viral
extinction [27,61–63]. Interference by defectors was specific for
their corresponding standard viruses, was not due to induction of
IFN or other unspecific cellular effectors, and it required
replication of the interfering genomes [27,61,63]. In consequence,
the presence in the infected cell of a mutagenic nucleotide together
with an antiviral inhibitor may jeopardize extinction because the
inhibitor will reduce replication of interfering genomes. This has
been addressed experimentally in the present study, and, indeed,
GU, but not R, attenuated the interfering activity exerted by a
combination of a polymerase and capsid mutant of FMDV. In
agreement with the attenuation of interference by GU, the
decrease in FMDV infectivity, viral load and attainment of viral
extinction are more effective with a sequential +GU,+R treatment
than with the combination treatment [+GU+R], or treatment with
R or GU alone (Figures 1 and 2). The differences were investigated
using a constant R concentration of 5 mM, and GU concentra-
tions in the range of 16 mM to 20 mM. Although eventually all
treatment regimes achieved extinction (Figure 2C), the sequential
+GU,+R treatment led earlier to low infectivity and RNA levels
than the corresponding combination treatment (Figure 2B). In an
Figure 4. Schematic representation of the theoretical model for virus evolution. Four different viral types (circles and hexagons) describe
the viral population: wild-type susceptible to the inhibitor (WTs), wild-type resistant (WTr), defective susceptible (Ds), and defective resistant (Dr). WTr
are generated through mutation by the WTs type. Any wild-type individual can produce defectors under replication. The rates of generation of
resistants and defectors are linked, such that increases in the mutation rate increase proportionally both rates (the former being substantially smaller
than the latter). From the viewpoint of the virus, increased mutagenesis has two opposed effects: it promotes the appearance of resistant forms but
at the same time enhances the appearance of defectors, which can induce extinction. Survival thus appears as a subtle balance between both trends.
doi:10.1371/journal.ppat.1000658.g004
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sustained decrease in viral load may provide the host immune
response with an opportunity to effect viral clearance. An added
benefit of a sequential treatment is that toxicity or antagonistic
effects, additional to suppresion of interference, derived from
simultaneous administration of two drugs, are avoided.
It must be stressed that the benefits of a sequential treatment do
not hold for standard non-mutagenic antiviral agents, for which
combination treatments are essential to prevent selection of
inhibitor-resistant mutants [40,41,73]. According to our experi-
mental and theoretical results there are two key influences that
favor the inhibitor-mutagen sequential treatment, and that do not
operate when only non-mutagenic inhibitors are involved. One is
that the mutagenic agent increases the probability of selection of
inhibitor-escape mutants, and this probability increases with the
viral load. The second influence is that the interfering activity of
defector genomes is important to drive the population towards
extinction. The administration of the inhibitor will produce a
decrease in viral load, that will render the system more susceptible
to mutagenesis-mediated extinction, allowing expression of
interfering activities associated with the mutagenized spectrum of
mutants [33]. No mutations in the 2C-coding regions that confer
resistance to GU have been detected in passage 2 of sequential or
combination treatment in the presence of 16 mM GU (experiment
of Figure 2). Thus, GU-escape mutants were not a factor in the
disadvantage of the combination treatment. At present, we cannot
exclude that other mechanisms may also contribute to the
observed benefits of a sequential inhibitor-mutagen treatment.
The experimental results are supported by a simple model of
viral evolution taking into account the minimal ingredients that
describe the experimental system. Our numerical results indicate
that four different viral types, as discussed, are essential to
reproduce the observed dynamics. According to the model, the fast
generation and fixation of resistant mutants (controlled by
parameter m, and the number G of replication cycles inside the
cell) is the essential mechanism conferring advantage to sequential
therapy. In the absence of a mutagenic activity, the model predicts
benefits of combination therapy, as in previous models of virus
dynamics in connection with drug therapy [40]. Future work will
explore the range of parameters that provide the strongest
advantages to either therapy, as well as the relevance of other
dynamical rules (such as the inclusion of lethal mutations or more
detailed relationships between genomic mutations and their effect
on fitness) in the behavior of the model system. For example, the
current model predicts that as the interfering activity of defectors
increases, the advantage of the sequential over the combination
treatment is gradually lost (Manrubia et al. unpublished results). It
is not known why under strong suppression (unrealistic for mutants
generated by random mutagenesis within the quasispecies) the
response of the system is that expected for administration of
classical, non-mutagenic antiviral inhibitors, and this point is
under investigation.
The results reported here can impact current antiviral therapies
that involve R, such as the combination of pegylated IFN-a (PEG-
IFN-a) and R for treatment of human HCV infections. In these
treatments, IFN can have multiple effects at the level of the entire
organisms, and also it is not clear whether ribavirin acts as a
mutagenic agent, which would imply a lethal mutagenic action, or
by other mechanisms, or combination of mechanisms [74–82]. For
patients who respond to IFN-a treatment, and their HCV load is
reduced, a sequential +IFN-a (or PEG- IFN-a),+R treatment may
be advantageous over the corresponding combination treatment.
Our experimental and theoretical results predict this to be true to
the extent that R acts as a mutagenic agent for HCV, and that
Figure 5. Dynamics of the model system in situations
analogous to the experimental setting. Total number of wild-type
individuals (either susceptible or resistant) as a function of the passage
number. Parameters are N=10
7, m=10
23, w=0.005 (in the absence of
mutagen), w=0.6 (in the presence of mutagen), G=5. (A) Behavior of
the population in the presence of mutagen, showing the high yield
attained under the natural mutation rate w=0.05 and the recovery of
the population when the mutagen acts during a limited number of
passages. For w=0.6, extinction supervenes at passage 5. (B) Effect of
different amounts of inhibitor in the population. This figure is
analogous to Figure 1. If the amount of inhibitor is not high enough
to guarantee extinction, resistant forms appear and are subsequently
fixed in the population, which reaches a level of viral yield comparable
to that in the absence of inhibitor after a sufficiently large number of
passages. (C) Effect of different therapies on the fate of the population.
The situations represented are analogous to those in Figure 2 (B–D), as
described in the legend. Note the different effectiveness of the
alternative treatments to achieve an undetectable number of WT
particles.
doi:10.1371/journal.ppat.1000658.g005
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However, R has multiple affects on cell metabolism [83–87] it is
not easy to assess which is the contribution of mutagenesis and
defector genomes, in the course of treatments of HCV infections
[34,66,87–90]. The first clinical trials, that consisted in the
administration of recombinant IFN-a to chronic non-A, non-B
hepatitis, resulted in improvement of aminotransferase levels and
liver histology [91]. Subsequent treatments, once HCV had been
identified, involved IFN-a alone or in combination with R [92,93].
Some early clinical trials documented benefits of a combination
[IFN-a,+R] treatment versus either treatment with IFN-a alone,
or sequential treatment first with R and then with IFN-a,i n
chronic HCV infections [94]. More recent trials established a
higher efficacy of PEG-IFN-a over conventional IFN-a,i n
combination treatments with R [95]. Other trials have compared
IFN-a or R monotherapy with combination therapies
or sequential therapies involving administration of R first
[74,96–99]. In a trial for the treatment of chronic HCV and
HIV-1 in doubly-infected hemophiliacs, IFN-a-2b was adminis-
tered as monotherapy for one month, and then oral R was added
to the treatment [100]. To our knowledge, no systematic trials
have involved sequential treatment with IFN-a first, and then with
R alone, precisely the protocol predicted to be more effective,
according to our results.
Exploration of sequential inhibitor-mutagenic treatments for
HCV infections may become more relevant in the face of the new
generation of specific inhibitors of HCV replication, now at
different stages of development for clinical practice [101,102]. Our
prediction should hold also for treatment of other chronic viral
infections, such as human hepatitis B virus for which both
mutagenic nucleoside analogues and non-mutagenic inhibitors are
available for treatment [103,104]. It is obvious, however, that
because of the complexities involved in pharmacological activities
in vivo [83–87], experiments with animal models are needed to
explore whether results in vivo will be those predicted by our model
experiments in cell culture, and by the theoretical study.
Materials and Methods
Cells and viruses
The origin of BHK-21 cells and procedures for cell growth in
Dulbecco’s modification of Eagle’s medium (DMEM), and for
plaque assays in semisolid agar have been previously described
[105,106]. The viruses used in the experiment are the following:
FMDV C-S8c1 is a plaque-purified derivative of serotype C isolate
C1 Santa Pau-Sp70 [106]. An infectious clone of FMDV C-S8c1,
termed pMT28 was constructed by recombining into a pGEM-1
plasmid subclones that represented the C-S8c1 genome, as
described [107,108]. Thus, FMDV pMT28 used in the experi-
ments is the progeny of infectious transcripts that express the
standard FMDV C-S8c1. Capsid (Q2027A) and polymerase (MD,
DMD and D3) mutants were previously described, and charac-
terized biologically and with an interference index [63,109]. To
control for the absence of contamination, mock-infected cells were
cultured and their supernatants were titrated in parallel with the
infected cultures; no signs of infectivity or cytopathology in the
cultures or in the control plaque assays were observed in any of the
experiments.
Treatment with guanidine hydrochloride (GU)
A solution of guanidine (GU) in DMEM was prepared at a
concentration of 50 mM, sterilized by filtration, and stored at 4uC.
Prior to use, the stock solution was diluted in DMEM (Dulbecco’s
modification of Eagle’s medium) to reach the desired concentra-
tion. For infections of BHK-21 cells with FMDV in the presence of
GU, no pretreatment of the cell monolayer with GU was
performed. After addition of FMDV and washing of the cell
monolayers, infections were allowed to continue in the presence of
GU. For each passage 2610
6 BHK-21 cells were infected with
supernatant of virus from the previous passage (0.2 ml), and the
infection allowed to proceed for about 24 h. The multiplicity of
infection (MOI) ranged from 1610
25 to 1610
21 PFU/cell, and
the MOI for each passage can be calculated from the infectivity
values given in the experiment (Figure 1). Infections in the absence
of GU, and mock-infected cells were maintained in parallel; no
evidence of contamination of cells with virus was observed at any
time.
Treatment with ribavirin (R)
A solution of R in PBS was prepared at a concentration of
100 mM, sterilized by filtration, and stored at 270uC. Prior to
use, the stock solution was diluted in DMEM to reach the desired
R concentration. For infections in the presence of R, cell
monolayers were pretreated during 7 h with 5 mM R prior to
infection. FMDV C-S8c1 was passaged serially in the absence or
in the presence of R (5 mM). After addition of FMDV and
washing of the cell monolayers, the infection was allowed to
proceed in the presence of the same concentration of R. For each
passage 2610
6 BHK-21 cells were infected with supernatant of
virus from the previous passage (0.2 ml) and the infection
continued for about 24 h. The multiplicity of infection (MOI)
ranged from 5610
26 to 1610
21 PFU/cell, and the MOI for each
passage can be calculated from the infectivity values given for each
experiment (Figures 2B, C, D). The passage experiments described
in Figures 1 and 2 occurred over a 24-hour period, and therefore
each passage is comprised of multiple replication cycles. Infections
in the absence of R, and mock-infected cells were maintained in
parallel; no evidence of contamination of cells with virus was
observed at any time.
Assessment of FMDV extinction
FMDV was considered extinct when no virus infectivity and no
viral RNA that could be amplified by a highly sensitive RT-PCR
protocol, could be demonstrated neither in the supernatant of the
passage that harbors the putatively extinghuished virus, nor after 3
blind passages in BHK-21 cells, in the absence of any drug.
Multiple highly sensitive RT-PCR amplification reactions that
yield short cDNAs were carried out to ascertain extinction. Some
of the gels that did not show a visible band were overexposed to
ascertain absence of detectable DNA. These criteria to consider
FMDV extinct [33,36,37,59,66] have now been extended to show
that no infectivity or RT-PCR amplifiable material can be
retrieved after passaging of the cells that harbor the putatively
extinguished virus. This extension was prompted by the
observation that FMDV subjected to hundreds of plaque-to-
plaque transfers could lose capacity to form plaques and yet
maintain intracellular RNA [110]. It should be noted that
infectivity below the level of detection did not necessarily imply
extinction (see Figure 2).
RNA extraction, RNA quantification, cDNA synthesis and
PCR amplification
Viral RNA was extracted from the medium of infected cells
using Trizol (Invitrogen) as previously described [110]. Reverse
transcription was performed with AMV reverse transcriptase
(Promega), and PCR amplification was carried out using Expand
High Fidelity (Roche), as specified by the manufacturers. The 3D-
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A2SacI (59- CACACATCGACCCTGAACCGCACCACGA;
sense orientation; the 59 nucleotide corresponds to genomic
residue 6581), and oligonucleotide AV4 (59- TTCTCT-
TTTCTCCATGAGCTT; antisense orientation; the 59 nucleotide
corresponds to genomic residue 7071). Genomic residues are
numbered as described in [111]. Amplification products were
analyzed by agarose gel electrophoresis using HindIII-digested F-
29 DNA as molar mass standards. Negative controls (amplifica-
tions in the absence of RNA) were included in parallel to ascertain
absence of contamination by template nucleic acids.
Quantification of FMDV RNA
Real time quantitative RT-PCR was carried out using the Light
Cycler RNA Master SYBR Green I kit (Roche), according to the
instructions of the manufacturer and as described previously for
FMDV RNA [110]. The 2C-coding region was amplified using as
primers oligonucleotide 2CR2 (59- GGCAAACCCTTCAGCAG-
TAAG; sense orientation; the 59 nucleotide corresponds to
genomic residue 4924), and oligonucleotide 2CD3 (59- CGCT-
CACGTCGATGTCAAAGTG; antisense orientation; the 59
nucleotide corresponds to genomic residue 5047). Quantification
was relative to a standard curve obtained with known amounts of
FMDV RNA, synthesized by in vitro transcription of FMDV cDNA
(plasmid pMT28). The specificity of the reaction was monitored by
determining the denaturation curve of the amplified DNAs.
Negative controls (without template RNA and RNA from mock-
infected cells) were run in parallel with each amplification
reaction, to ascertain absence of contamination with undesired
templates.
Transcription of viral RNA and electroporation of BHK-21
cells
Plasmid DNA was linearized by cleavage with the appropiate
restriction enzymes (pO1K/C-S8c1, and the capsid mutant
plasmids with Hpa I and pMT28 derivates with Nde I, as previously
described [63]). Then, the plasmids were purified by Wizard PCR
Preps DNA purification resin (Promega), and dissolved in RNase-
free water. FMDV RNA was transcribed from the linearized
plasmids by using the Riboprobe in vitro transcription system
(Promega). The mixture contained transcription buffer (Promega),
10 mM dithiothreitol, 0.48 units/ml RNasin, 1 mM each of
ribonucleoside triphosphates, 4 ng/ml linearized plasmid DNA,
and 0.3 or 0.4 units/ml SP6 or T7 RNA polymerase; it was
incubated for 2 h at 37uC. The RNA concentration was estimated
by agarose gel electrophoresis, with known amounts of rRNA as
markers.
To electroporate BHK-21 cells with RNA transcribed in vitro,
subconfluent cells were harvested, washed with ice-cold phos-
phate-buffered saline (PBS), and resuspended in PBS at a density
of about 2.5610
6 cells/ml. Aliquots (50–80 ml) of transcription
mixture with the apropiate amount of RNA were added to 0.4 ml
of cell suspension, and the mixtures were transferred to 2 mm
electroporation cuvettes (Bio-Rad). Electroporation was performed
at room temperature by two consecutive 1.5 kV, 25 mF pulses
using a Gene Pulser apparatus (Bio-Rad), as described [63]. As
control, BHK-21 cells were electroporated with 50–80 mlo f
transcription mixture in PBS to monitor absence of contamina-
tion. The cells were then resuspended in growth medium and
seeded onto culture plates. At 3, 5 and 6 hours post-electropora-
tion, samples of cells and culture medium were withdrawn and
after three cycles of freezing at 270uC and thawing at room
temperature, the lysate was stored at 270uC. Mock-coelectropo-
rated cultures were treated in parallel and served as control in the
titration of virus infectivity. No evidence of viral contamination
was obtained in any of the experiments.
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